Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that the company (which includes its subsidiaries and associate companies, ‘Sun Pharma’) has received approval from the U.S. Food and Drug Administration (FDA) for LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the treatment of severe alopecia areata. A copy of the press release on this update is enclosed, and it shall be released after submitting this intimation.

The above information is a part of company’s filings submitted to BSE.